Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Povorcitinib (JAK1) in Vitiligo. The expected timing is based on the latest available company guidance and may change.
STOP-V1, STOP-V2 trials. 10/11/23- Positive 52-wk data from Ph2b study. 7/29/25- Two Ph3 trials ongoing with data in 2026. 03/28/26:- Topline Phase 3 vitiligo data anticipated in Mid-2026.
Verification
Confirm timing and program details against the company announcement or filing.